Home Companies Catalysts Deep Dives
Alunbrig brigatinib APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaOncology
Launch2017-04-28
US LOE2031-01-01
Peak Sales Est$500M
Formulations[{"id":"alunbrig-po","route":"PO","setting":"OUTPATIENT","frequency":"Once daily","is_primary":true}
Companies
TAK (ORIGINATOR)100%
Mechanism: ALK inhibitor
Expert: Second-generation ALK tyrosine kinase inhibitor with CNS penetration and activity against resistance mutations.
Everyday: Blocks a mutated protein that drives certain lung cancers.
Targets: ["ALK"]
Revenue History
PeriodRevenue ($M)
2024$350M
Programs (1)
IndicationStageKey StudyRegional Status
ALK+ NSCLCAPPROVEDALTA-1L[{"stage":"APPROVED","region":"US","approval_date":"2017-04-28"},{"stage":"APPRO
Notes
Second-generation ALK inhibitor for ALK+ NSCLC. Strong CNS activity. Competes with Alecensa, Lorbrena.
Data from Supabase · Updated 2026-03-24